Scholars Central

OtherPublished 23 Jul 2016

Using simulation to optimize adaptive trial designs: applications in learning and confirmatory phase trials

Authors: Jurgen Hummel, Song Wang & John Kirkpatrick

Clinical Investigation

Volume 5 · Issue 4 · Pages 401–413

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Failures in Phase III clinical trials have a major impact on escalating drug development costs. Clinical trial simulation can improve decisions made in learning Phase I and Phase II studies, leading to better designs and reduced chance of failure in high-cost, confirmatory Phase III trials. In adaptive design trials – which use early findings to modify the trial toward the most promising dose, sample size or patient population – simulation is instrumental in guiding selection of optimal design modifications. In this article, the authors present case studies demonstrating the benefits of simulations to identify maximum tolerated dose in Phase I, define dose–response relationships in Phase II, and determine the best type and timing of interim analyses in Phase III.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Jurgen Hummel”
  • BylineArticles whose byline prints “Song Wang & John Kirkpatrick”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels